Aclaris Therapeutics starts Phase 2b trial of modzatinib for lichen planus
ACRS•Aclaris Therapeutics initiated the Phase 2b ALPHA trial of modzatinib for moderate-to-severe lichen planus, enrolling approximately 100 participants across two doses and placebo. Top-line results are expected in the second half of 2027.
1. Trial design and timing
The placebo-controlled trial will evaluate two doses in approximately 100 participants whose disease is inadequately controlled with topical therapies. Enrollment will begin with patients who have oral erosive lichen planus, and top-line results are expected in the second half of 2027.
2. Fast Track designation
Modzatinib has FDA Fast Track designation for moderate-to-severe lichen planus, which has no FDA-approved therapies.




